Oxford Nanopore Technologies (LSE:ONT) ROCE % : -24.21% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Oxford Nanopore Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Oxford Nanopore Technologies's annualized ROCE % for the quarter that ended in Dec. 2023 was -24.21%.

Oxford Nanopore Technologies ROCE % Historical Data

The historical data trend for Oxford Nanopore Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Nanopore Technologies ROCE % Chart

Oxford Nanopore Technologies Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-56.77

-42.97

-34.91

-11.13

-20.78

Oxford Nanopore Technologies Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial					-43.23	-7.23	-14.76	-18.71	-24.21

Oxford Nanopore Technologies ROCE % Calculation

Oxford Nanopore Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-147.562	/	( ( (823.89 - 91.539)	+	(777.062 - 89.199) )	/ 2 )
	=	-147.562	/	( (732.351	+	687.863)	/ 2 )
	=	-147.562	/	710.107
	=	-20.78 %

Oxford Nanopore Technologies's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-164.144	/	( ( (758.823 - 90.881)	+	(777.062 - 89.199) )	/ 2 )
	=	-164.144	/	( ( 667.942	+	687.863 )	/ 2 )
	=	-164.144	/	677.9025
	=	-24.21 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Oxford Nanopore Technologies (LSE:ONT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Oxford Nanopore Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Oxford Nanopore Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford Nanopore Technologies (LSE:ONT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford Nanopore Technologies PLC (LSE:ONT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ONTTF:USA ONTl:UK 4R0:Germany

Address

Edmund Halley Road, Gosling Building, Oxford Science Park, Oxford, Oxfordshire, GBR, OX44DQ

Website

https://www.nanoporetech.com

Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The Group is primarily involved in researching, developing, manufacturing, and commercializing the world's only commercial nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables our customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science.

Oxford Nanopore Technologies (LSE:ONT) Headlines

No Headlines